Goldman Sachs
LOGC

Goldman Sachs’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Goldman Sachs’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-12,298
Closed -$4K – 6766
2022
Q2 		$4K Sell
12,298
-495,892
-98% -$251K ﹤0.01% 6371
2022
Q1 		$346K Sell
508,190
-285
-0.1% -$313 ﹤0.01% 5588
2021
Q4 		$1.18M Buy
508,475
+466,289
+1,105% +$1.58M ﹤0.01% 4704
2021
Q3 		$193K Sell
42,186
-12,844
-23% -$56.5K ﹤0.01% 5734
2021
Q2 		$244K Buy
55,030
+20,423
+59% +$104K ﹤0.01% 5640
2021
Q1 		$252K Buy
34,607
+4,317
+14% +$35.5K ﹤0.01% 5517
2020
Q4 		$231K Buy
30,290
+976
+3% +$6.53K ﹤0.01% 5017
2020
Q3 		$266K Sell
29,314
-10,323
-26% -$78.3K ﹤0.01% 4797
2020
Q2 		$335K Buy
39,637
+13,567
+52% +$89.3K ﹤0.01% 4574
2020
Q1 		$129K Buy
26,070
+898
+4% +$6.98K ﹤0.01% 4880
2019
Q4 		$181K Buy
25,172
+1,480
+6% +$13.4K ﹤0.01% 4921
2019
Q3 		$256K Buy
+23,692
New +$253K ﹤0.01% 4739
2019
Q1 		– Sell
-64,949
Closed -$675K – 5549
2018
Q4 		$675K Buy
+64,949
New +$785K ﹤0.01% 4204

Other funds holding LOGC

OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $91.8B AUM 38.24% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Bridgeway Capital Management
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Goldman Sachs's LOGC Position: Q3 2022 in Review

Goldman Sachs sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q3 2022, closing a stake of 12,298 shares — an estimated $4K sold.

Goldman Sachs first reported a position in LOGC in Q4 2018 and held it in 13 quarters. The position peaked at $1.18M in Q4 2021. 39 funds tracked by Wall St. Rank hold LOGC as of Q3 2022.

  • Goldman Sachs reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Goldman Sachs sold 12,298 LogicBio Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $4K.
  • Goldman Sachs first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q4 2018 and held it in 13 quarters.
  • Goldman Sachs's LogicBio Therapeutics, Inc. Common Stock position peaked at $1.18M in Q4 2021.
  • 39 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Goldman Sachs's 13F filing for Q3 2022, filed 14 Nov 2022.